Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations (CROSBI ID 260881)
Prilog u časopisu | pregledni rad (stručni)
Podaci o odgovornosti
Prpić, Marin ; Franceschi, Maja ; Romić, Matija ; Jukić, Tomislav ; Kusić, Zvonko
engleski
Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations
Initial treatment of the majority of patients with differentiated thyroid cancer (DTC) includes total thyroidectomy. Postoperative ablation therapy with radioactive iodine (I- 131) is indicated in all high-risk patients, however, there is disagreement regarding its use in low- and intermediate-risk patients. Over the last few decades, thyroglobulin (Tg) has been established as the primary biochemical tumor marker for patients with DTC. Thyroglobulin can be measured during thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid hormone withdrawal or the use of human recombinant TSH. In many studies, the cut-off value for adequate Tg stimulation is a TSH value >= 30 mIU/L. However, there is an emerging body of evidence suggesting that this long-established standard should be re- evaluated, bringing this threshold into question. Recently, a risk stratification system of response to initial therapy (with four categories) has been introduced and Tg measurement is one of the main components. The relationship between the Tg/TSH ratio and the outcome of radioiodine ablation has also been studied, as well as clinical significance of serum thyroglobulin doubling-time. The postoperative serum Tg value is an important prognostic factor that is used to guide clinical management, and it is the most valuable tool in long term follow-up of patients with DTC.
Thyroglobulin ; Thyroid neoplasms ; Thyroidectomy ; Iodine radioisotopes ; Biomarkers, tumor ; Thyroid hormones ; Croatia
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
57 (3)
2018.
518-527
objavljeno
0353-9466
1333-9451
10.20471/acc.2018.57.03.16
Povezanost rada
Temeljne medicinske znanosti, Kliničke medicinske znanosti